Satellos Bioscience Inc MSLE 深 沪
已收盘 05-15 16:00:00 美东时间
7.01
-0.160
-2.23%
华盛通- 最 高7.3599
- 今 开7.17
- 成交量 4.33万股
- 最 低 6.86
- 昨 收 7.17
- 总市值 14.60万
- 52周最高 13.3949
- 市盈率 静 --
- 换手率 0.21%
- 52周最低 5.50
- 委 比 99.24%
- 总股本 2.08万
- 历史最高 13.3949
- 量 比 1.09
- 振 幅 6.97%
- 历史最低 5.50
- 每 手 1
- 风险率 2.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.
05-15 19:09
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.
04-28 23:26
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Satellos Bioscience FY2025 publishes MD&A report; net loss widens to $24,873 USD
Satellos Bioscience FY2025 publishes MD&A report; net loss widens to $24,873 USD Satellos published its MD&A outlining progress for SAT-3247, including Phase 1a safety and pharmacokinetic results from 72 healthy volunteers and Phase 1b dosing in five adult Duchenne muscular dystrophy patients over 2
03-27 20:31
Satellos Bioscience GAAP EPS of -$1.70
Satellos Bioscience press release (MSLE): FY GAAP EPS of -$1.70. Satellos had cash and cash equivalents and short-term investments of $27.7 million as of Dec. 31, 2025, compared with $48.5 million on ...
03-27 19:06
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos Bioscience Inc. announced its financial and operational highlights for 2025, including a US$57.2 million equity financing and the commencement of trading on the Nasdaq Global Market. The company initiated a Phase 2 clinical trial, BASECAMP, for its Duchenne muscular dystrophy (DMD) treatment SAT-3247, and presented positive interim data from the TRAILHEAD trial, showing sustained or improved grip strength in participants. SAT-3247 also d...
03-27 11:00
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
Satellos Bioscience Inc. announced interim data for SAT-3247 at the MDA conference, highlighting continued improvement in handgrip strength, biomarker reductions, and muscle regeneration potential in DMD and FSHD. The Phase 2 TRAILHEAD study showed stability in elbow and shoulder strength, while Phase 1a/b results demonstrated reductions in DMD biomarkers within two weeks. Preclinical FSHD data indicated enhanced muscle strength. Enrollment remai...
03-10 11:00
